I didn't say we're here yet but i do think the market is shifting to testing everyone for EGFR, KRAS and ALK mutations (see PF-02341066). Dr. West is certainly correct the data needs to be actionable and for him it's not. And i'm sure it will take longer than i think, as far as i know most colorectal oncs still aren't testing for KRAS status yet prescribe Erbitux which is baffling. I'll be curious to see the results of the Roche front line study Genisi cited.
Market Data 
Markets 
AI
